Comparison of antitumor activity of platinum analogs using human lung cancer cells.

概要

論文の詳細を見る
The antitumor activity of four newly developed platinum analogs, carboplatin, 254-S, DWA2114R, and NK121, was compared with that of cisplatin in five human lung cancer cell lines and nineteen specimens from lung cancer patients. The antitumor activity was evaluated by the ratio of maximum tolerated dose of the drug examined/70% lethal dose determined by colony assay. Regarding this ratio as the ordered metric scale of antitumor activity, cisplatin was most potent, followed by 254-S, and carboplatin. Carboplatin, DWA2114R and NK121 were less potent than cisplatin or 254-S, and there were no significant differences among them in degree of antitumor activity. In addition, cross-resistance patterns to these five platinums were investigated using an adriamycin-resistant small cell lung cancer subline, SBC-3/ADM. The SBC-3/ADM cells were 1.7 to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114 R, than the parent line, SBC-3, whereas the cells were 2.0-fold more sensitive to 254-S. These data suggest the usefulness of 254-S in the treatment of lung cancer.
特定非営利活動法人日本肺癌学会の論文